After Stroke, Rehabilitation Therapy Determines the Quality of Life of Patients

 With only 10% full recovery, that rehabilitation therapy IS A COMPLETE FUCKING FAILURE! There is NO DEFENSE against that! The tyranny of low expectations excuse will result in immediate firings!

After Stroke, Rehabilitation Therapy Determines the Quality of Life of Patients

JAKARTA - Stroke management does not stop when the patient passes the critical phase. After the initial attack is handled, the therapy process continues in an effort to restore body functions while preventing wider brain damage.

At this stage, support for the function of nerve cells becomes crucial, because brain cells are still in a vulnerable condition due to disruptions in the supply of oxygen and energy.(Yeah, during the first week, hundreds of millions to billions of neurons continue to die! And your fuckingly incompetent? doctor IS DOING NOTHING TO STOP THAT! I'd suggest charging $1000 a dead neuron, that might concentrate their minds!)

In Indonesia, stroke is still one of the leading causes of death and disability, with a prevalence of 8.3 per 1,000 population based on the Indonesian Health Survey (SKI) 2023.

In addition to emergency treatment, the next challenge is to minimize the subsequent neurological damage that can affect the quality of life of patients in the long term.

To answer this need, PT Pyridam Farma Tbk presents a neuroprotective therapy called Cytoflavin. This therapy is designed to help maintain cell metabolism function and support cellular respiration processes, especially when the brain condition experiences oxygen deficiency.

In the condition of ischemic stroke, mitochondrial dysfunction causes decreased energy production, thereby accelerating brain tissue damage. An approach to therapy that supports the utilization of oxygen and the formation of energy at the cellular level is considered important for maintaining the viability of nerve cells during the critical phase until the beginning of recovery.

This approach is increasingly relevant given the high rate of post-stroke disability which impacts the patient's daily activities. Appropriate interventions from the early to subacute phases are considered to play a major role in determining long-term recovery outcomes.

Throughout 2025, the company was also involved in various scientific forums in the field of neurology as part of education for medical personnel. This therapy has reportedly been used in hundreds of hospitals in Indonesia, including stroke referral facilities.

Specialist neurologist from National Hospital Dr. Cipto Mangunkusumo, Mohammad Kurniawan, conveyed his views regarding the development of this therapy.

"Seeing the manufacturing process and cutting-edge technology of Cytoflavin in Russia makes me amazed. The standards they apply are very good in ensuring the efficiency of production and the efficacy of pharmacological products. This kind of pharmaceutical innovation with precision is what is needed to provide the best support for patients who need intensive treatment such as stroke in the acute phase," he said.

Meanwhile, the Director of PT Pyridam Farma Tbk, Antes Eko Prasetyo, highlighted the trend of increasing stroke cases at productive age as a challenge in itself.

"We are committed to continuing to provide health solutions that are relevant to the needs of the community and hospitals today. Through the distribution of Cytoflavin, we want to ensure that health workers in Indonesia have access to the right therapeutic options to support the optimal recovery process for stroke patients," he said.

Through the development of neuroprotective therapy, it is hoped that stroke treatment in Indonesia can be more comprehensive, not only saving lives, but also helping patients achieve better quality of life after the recovery period.(Quality of life is NOT the survivors goal; FULL RECOVERY IS! GET THERE!)